<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211692</url>
  </required_header>
  <id_info>
    <org_study_id>MVRI001</org_study_id>
    <nct_id>NCT00211692</nct_id>
  </id_info>
  <brief_title>Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial</brief_title>
  <official_title>Prospective Randomized Pilot Study of Daily Consensus Interferon (CIFN) and Ribavirin for 52 Wks vs Extended Duration 72 Wks Based on Virologic Response for the Initial Treatment of Difficult-to-treat Patients With Chronic HCV Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Veterans Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>InterMune</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kadmon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>San Diego Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Minneapolis Veterans Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data have suggested that consensus interferon (CIFN) has greater antiviral activity in vitro&#xD;
      compared with interferon alfa-2a or alfa-2b. Several clinical studies also suggest that CIFN&#xD;
      has greater antiviral activity in patients with genotype 1 hepatitis C infection,&#xD;
      particularly if given as a daily injection. These data indicate that the use of a regimen of&#xD;
      daily CIFN and ribavirin will lead to greater virologic response rates compared with&#xD;
      pegylated interferon alfa-2b and ribavirin in patients with genotype 1 infection, with&#xD;
      comparable adverse events. Emerging data indicate that HCV genotype 1 patients with a delayed&#xD;
      virologic response to initial therapy may benefit from an extended duration of therapy.&#xD;
      Therefore, the goals of this pilot study are to determine the tolerability and efficacy of&#xD;
      daily CIFN plus ribavirin when given for 52 weeks or an extended duration of therapy. The&#xD;
      target population will consist of &quot;difficult-to-treat&quot; patients, defined as having the&#xD;
      following characteristics: genotype 1, a North American patient population, predominantly&#xD;
      male gender, and no specific exclusions for pre-existing psychiatric or substance abuse&#xD;
      co-morbidities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current treatment for hepatitis C is a pegylated interferon alfa plus ribavirin. This&#xD;
      treatment is inadequate for patients with HCV genotype 1, since the majority of patients do&#xD;
      not respond (termed non-responders) or respond but relapse (termed relapsers) following&#xD;
      termination of these treatments. Data from the Veterans Health Administration (VHA) Hepatitis&#xD;
      C Registry and community hospitals indicate that the large majority of patients identified&#xD;
      with hepatitis C have characteristics associated with a poor treatment response and remain&#xD;
      untreated at this time. Data have suggested that consensus interferon (CIFN, CIFN or&#xD;
      interferon alfacon-1) has greater antiviral activity in vitro compared with interferon&#xD;
      alfa-2a or alfa-2b. Preliminary data indicate that more patients with genotype 1 can respond&#xD;
      to CIFN and ribavirin than current standard treatments, due to the fact that approximately&#xD;
      25% of patients who are nonresponders to pegylated interferon and ribavirin may have a&#xD;
      sustained response to a regimen of daily CIFN and ribavirin. Furthermore, difficult to treat&#xD;
      patients may benefit from a longer duration of therapy than the standard 48 week regimen&#xD;
      based on when an initial virologic response to therapy occurs.&#xD;
&#xD;
      Aims: To determine the safety and efficacy of (A) daily CIFN (15 mcg/d sq) and ribavirin&#xD;
      (1-1.2 gm/d PO) given for 52 weeks, vs (B) daily CIFN (15 mcg/d sq) and ribavirin (1-1.2 gm/d&#xD;
      PO) given for 52 to 72 weeks for treatment-na√Øve patients with hepatitis C genotype 1, with&#xD;
      treatment duration based on the virologic response during the initial 24 weeks.&#xD;
&#xD;
      Methods: Patients who meet eligibility criteria will be stratified by race and randomized to&#xD;
      one of two treatment arms, and all patients will have viral kinetics measured by quantitative&#xD;
      PCR at weeks 4,8,12,16,20 and 24. Patients in treatment arm A will follow &quot;standard&quot; stopping&#xD;
      rules, i.e., if there is not a 2-log drop in viremia by 12 weeks the treatment will be&#xD;
      discontinued, otherwise they will all receive 52 weeks of treatment if they also are&#xD;
      qualitative PCR negative by week 24. In treatment arm B the patients will be monitored&#xD;
      monthly until they have a virologic response (defined as &gt;2 log drop in viral levels from&#xD;
      baseline) by quantitative PCR for up to 24 weeks. Once they have a virologic response by&#xD;
      quantitative PCR their treatment will be continued for an additional 48 weeks. In both&#xD;
      groups, treatment will be stopped if the patients do not become negative for HCV RNA by&#xD;
      qualitative PCR by 24 weeks on therapy. A total of 192 patients at up to 10-20 sites will be&#xD;
      recruited. The primary endpoint would be the number who achieve a sustained virologic&#xD;
      response; secondary endpoints are the percentage of patients who complete therapy, have&#xD;
      significant adverse events, and the relationship of early virologic response at each 4 week&#xD;
      period between 4 and 24 weeks and those who achieve a sustained virologic response.&#xD;
&#xD;
      Sample size determination: To detect an absolute difference of 20% or more in sustained&#xD;
      virologic response between treatment arms A and B; the Log-rank test is performed at the&#xD;
      alpha level of .05 and the test is maintained at least 80 percent statistical power; it is&#xD;
      estimated that a total of 96 patients in each treatment arm will be required.&#xD;
&#xD;
      Analysis: Univariate and multivariate analysis will be used to determine factors associated&#xD;
      with final endpoints. Subgroup analyses will be done based on time to early virologic&#xD;
      response and duration of therapy each stratification. The primary and secondary endpoints&#xD;
      will be determined on an intention-to-treat basis starting with all patients that receive at&#xD;
      least one dose of study medications. The primary and secondary endpoints will also be&#xD;
      determined in a per-protocol analysis on those patients who take 80% of the prescribed CIFN&#xD;
      and 80% of the prescribed ribavirin for 80% of the time.&#xD;
&#xD;
      Significance: The current initial treatment of pegylated interferon alfa and ribavirin for&#xD;
      patients with hepatitis C who are genotype 1 and have other &quot;difficult-to-treat&quot;&#xD;
      characteristics is inadequate. The results of this trial are needed to demonstrate the safety&#xD;
      and efficacy of two regimens of daily CIFN and ribavirin. Since the large majority of&#xD;
      hepatitis C patients in VA and other community hospitals fall into this category, the results&#xD;
      of this trial may influence the potential treatments recommended for these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint Would be the Number Who Achieve a Sustained Virologic Response.</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
    <description>Overall sustained virologic response for entire cohort and individual sustained virologic response for different arms of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing Early From Study Treatment</measure>
    <time_frame>through end of study up to 72 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Achieving SVR Categorized by Time of Response</measure>
    <time_frame>24 weeks after end of treatment</time_frame>
    <description>rapid virologic response assessed at 4 weeks, early virologic response assessed at 8-12 weeks, late virologic response assessed at 16-24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Number of Serious Adverse Events</measure>
    <time_frame>through end of study up to 72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A consensus interferon+rbv 52 wks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B CIFN variable duration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>consensus interferon (Interferon Alfacon-1) and ribavirin</intervention_name>
    <description>CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)</description>
    <arm_group_label>Group A consensus interferon+rbv 52 wks</arm_group_label>
    <other_name>interferon alfacon-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consensus Interferon alfa (CIFN) and ribavirin</intervention_name>
    <description>CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)</description>
    <arm_group_label>Group A consensus interferon+rbv 52 wks</arm_group_label>
    <arm_group_label>Group B CIFN variable duration</arm_group_label>
    <other_name>interferon alfacon-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Chronic hepatitis C. This is defined as the documentation of the presence of circulating&#xD;
        hepatitis C virus by a positive hepatitis C PCR test and a positive HCV genotype test for&#xD;
        genotype 1, and a liver biopsy (within the previous 5 years) that is compatible with&#xD;
        chronic hepatitis. In the case of patients that have refused liver biopsies a clinical&#xD;
        diagnosis of chronic hepatitis C is required.&#xD;
&#xD;
        2. Positive HCV RNA by PCR, Genotype 1, treatment naive 3. Age 18-65 years. 4. Patient must&#xD;
        be able to give informed consent. 5. Eligible for interferon alfa and ribavirin-based&#xD;
        antiviral treatment:&#xD;
&#xD;
          1. Reconfirmation and documentation that sexually active female patients of childbearing&#xD;
             potential are practicing adequate contraception. A urine pregnancy test obtained at&#xD;
             entry prior to the initiation of treatment must be negative.&#xD;
&#xD;
          2. Reconfirmation that sexually active male subjects are practicing acceptable methods of&#xD;
             contraception during the treatment period and for six months following the last dose&#xD;
             of study medication.&#xD;
&#xD;
          3. For patients with cirrhosis or stage 4 fibrosis on liver biopsy, they must have an&#xD;
             alpha fetoprotein (AFP) value &lt; 80 ng/mL obtained within 3 months prior to entry.&#xD;
             Cirrhotics with an alpha fetoprotein value &gt;30 ng/mL but &lt;80ng/mL may be enrolled&#xD;
             after a normal ultrasound or triphasic CT scan within the previous 3 months.&#xD;
             Cirrhotics with alpha fetoprotein levels up to 30 ng/ml must have an ultrasound or CT&#xD;
             scan within 6 months of enrolling that is negative for hepatocellular cancer. Patients&#xD;
             with an AFP &gt; 80 ng/mL may not be enrolled.&#xD;
&#xD;
        5) Compensated liver disease with the following laboratory results at entry:&#xD;
&#xD;
          -  Hemoglobin &gt;=to 12 gm/dL for females and &gt;= 13gm/dl for males&#xD;
&#xD;
          -  WBC &gt;= 2,000/mm3&#xD;
&#xD;
          -  Neutrophil &gt;=1,500/mm3&#xD;
&#xD;
          -  Platelets &gt;=75,000/mm3&#xD;
&#xD;
          -  Albumin &gt; 3.0 g/dL&#xD;
&#xD;
          -  Total bilirubin &lt;2.0&#xD;
&#xD;
          -  Serum creatinine &lt; 1.4 mg/dL&#xD;
&#xD;
          -  INR &lt;1.8&#xD;
&#xD;
          -  If diabetic, must have glycosylated Hgb test that demonstrates adequate control of&#xD;
             diabetes in the opinion of the investigator&#xD;
&#xD;
          -  TSH within normal limits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient unable or unwilling to participate.&#xD;
&#xD;
          2. Liver disease in addition to chronic hepatitis C (HBsAg positive, autoimmune liver&#xD;
             disease, hemochromatosis, PBC, PSC, alpha-1 antitrypsin deficiency, Wilson's disease,&#xD;
             etc.)&#xD;
&#xD;
          3. Decompensated liver disease, with history of encephalopathy, variceal bleeding, or&#xD;
             ascites or CHILD-PUGH class B or C.&#xD;
&#xD;
          4. Baseline BDI &gt; 19 or current suicidal or homicidal ideation. (Note: if baseline BDI is&#xD;
             &gt; 19 pt. will require a psychiatric evaluation and treatment; if deemed stable after&#xD;
             this he may be considered according to site PI clinical judgment.)&#xD;
&#xD;
          5. Current substance use disorder (Must be evaluated and demonstrate engagement and&#xD;
             compliance with care before they will be eligible).&#xD;
&#xD;
          6. Patients with active or uncontrolled psychiatric disease including patients who have&#xD;
             had recent prior severe psychiatric disease (hospitalized) within the last 2 years.&#xD;
&#xD;
          7. Accepted and reasonable exclusion criteria for interferon alfa and ribavirin based&#xD;
             treatments:&#xD;
&#xD;
        1) CNS trauma or active seizure disorders requiring medication. 2) Significant&#xD;
        cardiovascular dysfunction within the past 12 months 3) Poorly controlled diabetes mellitus&#xD;
        (in the opinion of the site PI). 4) Moderate or severe chronic pulmonary disease 5)&#xD;
        Clinically significant immunologically mediated disease 6) Hemoglobinopathies (e.g.,&#xD;
        Thalassemia) or any other cause of hemolytic anemia.&#xD;
&#xD;
        7) Any medical condition requiring, or likely to require during the course of the study,&#xD;
        chronic systemic administration of steroids.&#xD;
&#xD;
        8) Hypersensitivity to interferon alfa or ribavirin 9) Known anti-HIV positive 10)&#xD;
        Clinically significant retinopathy 11) Previous solid organ transplantation 12) Any&#xD;
        condition that, in the opinion of the investigator, will prevent the patient from being&#xD;
        compliant with study medications or appointments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel B. Ho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Department of Veterans Affairs</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, DeComarmond C, Smith CI, McKee DP, Boyd W, Kulig CC, Bini EJ, Pedrosa MC. U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for &quot;difficult-to-treat&quot; HCV genotype 1 patients. Dig Dis Sci. 2011 Mar;56(3):880-8. doi: 10.1007/s10620-010-1504-y. Epub 2011 Jan 11.</citation>
    <PMID>21221804</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <results_first_submitted>August 1, 2011</results_first_submitted>
  <results_first_submitted_qc>November 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2014</results_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minneapolis Veterans Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Samuel B. Ho</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>interferon alfa</keyword>
  <keyword>ribavirin</keyword>
  <keyword>interferon alfacon-1</keyword>
  <keyword>antiviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alfacon-1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with difficult-to-treat characteristics (78% VA) were enrolled at 7 Veterans Affairs (VA) and 2 community medical centers.</recruitment_details>
      <pre_assignment_details>All eligible patients were randomized and analysis performed using intention to treat.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A 52 Weeks Treatment</title>
          <description>Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)</description>
        </group>
        <group group_id="P2">
          <title>Group B Duration Based on Viral Response</title>
          <description>CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A 52 Weeks Treatment</title>
          <description>Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)</description>
        </group>
        <group group_id="B2">
          <title>Group B Duration Based on Viral Response</title>
          <description>CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" spread="8.0"/>
                    <measurement group_id="B2" value="49.8" spread="8.8"/>
                    <measurement group_id="B3" value="50.6" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint Would be the Number Who Achieve a Sustained Virologic Response.</title>
        <description>Overall sustained virologic response for entire cohort and individual sustained virologic response for different arms of study</description>
        <time_frame>24 weeks after the end of treatment</time_frame>
        <population>Convenience sample for pilot trial. Analysis is intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>A (52 Weeks Treatment)</title>
          </group>
          <group group_id="O2">
            <title>B (Duration Based on Viral Response)</title>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint Would be the Number Who Achieve a Sustained Virologic Response.</title>
          <description>Overall sustained virologic response for entire cohort and individual sustained virologic response for different arms of study</description>
          <population>Convenience sample for pilot trial. Analysis is intention to treat.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Discontinuing Early From Study Treatment</title>
        <time_frame>through end of study up to 72 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Early From Study Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Achieving SVR Categorized by Time of Response</title>
        <description>rapid virologic response assessed at 4 weeks, early virologic response assessed at 8-12 weeks, late virologic response assessed at 16-24 weeks</description>
        <time_frame>24 weeks after end of treatment</time_frame>
        <population>participants with analyzable data for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
          </group>
        </group_list>
        <measure>
          <title>Participants Achieving SVR Categorized by Time of Response</title>
          <description>rapid virologic response assessed at 4 weeks, early virologic response assessed at 8-12 weeks, late virologic response assessed at 16-24 weeks</description>
          <population>participants with analyzable data for this outcome</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rapid virologic response (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>early virologic response (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>late virologic response (n=9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Number of Serious Adverse Events</title>
        <time_frame>through end of study up to 72 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Number of Serious Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through end of study up to 72 weeks</time_frame>
      <desc>adverse events were collected for study population as a whole</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>other intolerable side effects</sub_title>
                <description>includes fatigue and irritibility</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>depression/anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samuel B. Ho, MD, Chief GI Section</name_or_title>
      <organization>VA San Diego Healthcare System</organization>
      <phone>858-552-8585 ext 2631</phone>
      <email>samuel.ho2@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

